Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

(2010) T. G. Oliver et al.   GENES & DEVELOPMENT

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

(2009) Neil Johnson et al.   MOLECULAR CELL

Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death

(2009) Bo Tian et al.   NATURE CELL BIOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion

(2008) Alan P. Brown et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE